DCF
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
-41.77%
US · US
CHD.US latest organized financial period shows revenue grew +1.57% YoY and net income grew +25.88% YoY. Current price is about 96.93 USD, while the model base case is about 44.05 USD; the current price sits +120% versus the base case. The page shows both reported and adjusted views; valuation still defaults to reported figures, while adjusted figures help isolate structured one-time-item impact. This summary is intended for public-information research and model review.
Annual financial metrics with switchable views. · Unit: USD
Price date: 2026/04/29 · Updated: 2026/04/29 15:26
Hover each model row to inspect formulas and inputs.
+120%
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
-41.77%
Uses recent net income as an owner-earnings proxy and discounts scenario growth.
+120%
Solves the forward FCF growth rate implied by the current price.
Current price implies roughly 6.0% annualized FCF growth.
Estimates earnings power value without assuming growth.
+175%
Updated: 2026/04/29 15:26
Collapsed by default. Expand to inspect structured one-time items and adjusted figures without making them the primary page focus.
A positive amountAfterTax means the item increased reported net income; a negative value means it reduced reported net income. Adjusted net income = reported net income minus total after-tax impact. Valuation defaults to reported figures; adjusted figures are shown to observe one-time-item impact.
| Period | Item | Category | After-tax impact | Confidence |
|---|---|---|---|---|
| 2025/12/31 | Asset impairment | Impairment | -8M USD | Medium |
| 2025/12/31 | Business sale gain/loss | Asset sale gain/loss | -46M USD | Medium |
| 2024/12/31 | Asset impairment | Impairment | -19M USD | Medium |
| 2023/12/31 | Asset impairment | Impairment | -21M USD | Medium |
| 2022/12/31 | Asset impairment | Impairment | -6M USD | Medium |
| 2021/12/31 | Asset impairment | Impairment | -35M USD | Medium |
| 2025/03/31 | Asset impairment | Impairment | -1M USD | Medium |
| 2024/09/30 | Asset impairment | Impairment | -282M USD | Medium |
| Period | Type | Revenue | Net Income | Adjusted net income | Free Cash Flow | Diluted EPS | Adjusted EPS |
|---|---|---|---|---|---|---|---|
| 2025/12/31 | Annual | 6B USD | 737M USD | 791M USD | 1B USD | 3.02 | 3.24 |
| 2024/12/31 | Annual | 6B USD | 585M USD | 604M USD | 976M USD | 2.37 | 2.45 |
| 2023/12/31 | Annual | 6B USD | 756M USD | 777M USD | 807M USD | 3.05 | 3.14 |
| 2022/12/31 | Annual | 5B USD | 414M USD | 420M USD | 706M USD | 1.68 | 1.7 |
| 2021/12/31 | Annual | 5B USD | 828M USD | 863M USD | 875M USD | 3.32 | 3.46 |
Total revenue recognized in each fiscal year.
Adjusted close trend. Current price sample covers: 2025/04/16 - 2026/04/29.